About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ARDX - Ardelyx| Previous Close | $5.23 | Open | $5.21 |
| Volume | 341.7K | Market Cap | 159.63M |
| Yield | Last Dividend |
| Ardelyx Inc (NASDAQ:ARDX) to Post Q3 202... | 10/24/20 |
| Ardelyx Inc (NASDAQ:ARDX) ??? Stock analysts at SVB Leerink increased their Q3 2020 earnings per share estimates for Ardelyx in a research report issu... | |
| Ardelyx Inc (NASDAQ:ARDX) Forecasted to ... | 10/22/20 |
| Ardelyx Inc (NASDAQ:ARDX) ??? SVB Leerink upped their Q3 2020 EPS estimates for Ardelyx in a research note issued on Tuesday, October 20th. SVB Leerin... | |
| Ardelyx and Kyowa Kirin Highlight New Da... | 10/22/20 |
| FREMONT, Calif. and TOKYO, Oct. 22, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class... | |
| Ardelyx Launches 'Can We Do Better?' Cam... | 10/22/20 |
| FREMONT, Calif., Oct. 22, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines... | |
| Zacks: Analysts Anticipate Ardelyx Inc (... | 10/20/20 |
| Brokerages expect Ardelyx Inc (NASDAQ:ARDX) to post $1.37 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two... | |
| Why This FDA Win for Ardelyx Is Definite... | 09/15/20 |
| No summary available. | |
| Ardelyx Announces FDA Acceptance for Fil... | 09/15/20 |
| FREMONT, Calif., Sept. 15, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicin... | |
| Ardelyx to Participate in Three Upcoming... | 09/08/20 |
| FREMONT, Calif., Sept. 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicine... | |
| Ardelyx Reports Second Quarter 2020 Fina... | 08/06/20 |
| FREMONT, Calif., Aug. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Ardelyx Selected as a Finalist in the Fi... | 08/03/20 |
| FREMONT, Calif., Aug. 3, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Ardelyx Appoints Veteran Biopharma Execu... | 06/08/20 |
| FREMONT, Calif., June 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Ardelyx Strengthens Management Team with... | 05/18/20 |
| FREMONT, Calif., May 18, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Will Ardelyx Continue to Surge Higher? | 05/12/20 |
| As of late, it has definitely been a great time to be an investor Ardelyx | |
| Ardelyx (ARDX) Upgraded to Strong Buy: H... | 05/11/20 |
| Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). | |
| Here's Why Momentum Investors Will Love ... | 04/28/20 |
| Does Ardelyx (ARDX) have what it takes to be a top stock pick for momentum investors? Let's find out. | |
| Ardelyx to file tenapanor application in... | 03/06/20 |
| Highlights from Ardelyx's (NASDAQ:ARDX) Q4 report released after the close: Net loss: ($19.8M) (+29%), loss/share: ($0.27) (+40%). Quick assets at yea... | |
| Ardelyx to Present at the Cowen and Comp... | 02/26/20 |
| FREMONT, Calif, Feb. 26, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ar... | |
| Ardelyx to Present at the 9th Annual SVB... | 02/19/20 |
| FREMONT, Calif., Feb. 19, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of A... | |
| The Daily Biotech Pulse: Axovant Surges ... | 12/20/19 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs D... | |
| Ardelyx : Announces Pricing of Upsized P... | 12/04/19 |
| FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. , a specialized biopharmaceutical company focused on developing innovative first-in-class ... | |
| Ardelyx Announces Pricing of Upsized Pub... | 12/04/19 |
| FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Ardelyx Announces Proposed Public Offeri... | 12/04/19 |
| FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| The Daily Biotech Pulse: Roche's Tecentr... | 12/04/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) A... | |
| The Daily Biotech Pulse: Tonix Says No S... | 11/27/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) ... | |
| Ardelyx to Present at the Piper Jaffray ... | 11/26/19 |
| FREMONT, Calif., Nov. 26, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-cl... | |
| Ardelyx and Kyowa Kirin Expand Partnersh... | 11/25/19 |
| FREMONT, Calif. and TOKYO, Nov. 25, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing f... | |
| The Daily Biotech Pulse: Endo's Cellulit... | 11/20/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) ... | |
| Zacks Investment Research Lowers Ardelyx... | 11/07/19 |
| Zacks Investment Research cut shares of Ardelyx (NASDAQ:ARDX) from a hold rating to a sell rating in a research note released on Monday morning, Zacks... | |
| Ardelyx Announces Presentation at Kidney... | 11/06/19 |
| Late breaking oral presentation to highlight data from AMPLIFY, the Pivotal Phase 3 Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrol... | |
| Ardelyx Reports Third Quarter 2019 Finan... | 11/06/19 |
| FREMONT, Calif., Nov. 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-cla... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
